Lp(a) Particles Mold Fibrin-Binding Properties of Apo(a) in Size-Dependent Manner-Reference-Cited by-同舟云学术

Lp(a) Particles Mold Fibrin-Binding Properties of Apo(a) in Size-Dependent Manner

Published:2002-07 Issue:7 Volume:22 Page:1232-1238
ISSN:1079-5642
Container-title:Arteriosclerosis, Thrombosis, and Vascular Biology
language:en
Short-container-title:ATVB

Author:

Kang Chantal¹,Dominguez Miguel¹,Loyau Stéphane¹,Miyata Toshiyuki¹,Durlach Vincent¹,Anglés-Cano Edouard¹

Affiliation:

1. From INSERM U460 (C.K., M.D, S.L., E.A.-C.), Faculté de Médecine Xavier Bichat, Paris, France; the Laboratory of Thrombosis Research (T.M.), National Cardiovascular Center Research Institute, Osaka, Japan; and Service Endocrinologie-Diabetologie (V.D.), Centre Hospitalo-Universitaire de Reims, Reims, France.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cardiology and Cardiovascular Medicine

Reference46 articles.

1. Protein composition of Lp(a) lipoprotein from human plasma

2. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen

3. Partial amino acid sequence of apolipoprotein(a) shows that it is homologous to plasminogen.

4. A structural assessment of the apo[a] protein of human lipoprotein[a]

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Correlation between circulating lipoprotein(a) levels and cardiovascular events risk in patients with type 2 diabetes;Heliyon;2024-09

2. Lipoprotein(a) as a Predictive Biomarker and Therapeutic Target for Acute Coronary Syndromes;Current Pharmaceutical Design;2023-09-06

3. Developing an SI-traceable Lp(a) reference measurement system: a pilgrimage to selective and accurate apo(a) quantification;Critical Reviews in Clinical Laboratory Sciences;2023-04-27

4. Commutability Assessment of Candidate Reference Materials for Lipoprotein(a) by Comparison of a MS-based Candidate Reference Measurement Procedure with Immunoassays;Clinical Chemistry;2023-01-16

5. Lipoprotein(a): Pathophysiology, measurement, indication and treatment in cardiovascular disease. A consensus statement from the Nouvelle Société Francophone d’Athérosclérose (NSFA);Archives of Cardiovascular Diseases;2021-12